BIO-TECHNE Corp Net Cash Provided by (Used in) Operating Activities, Continuing Operations
BIO-TECHNE Corp (TECH) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of $143.45 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2017-09-07
- BIO-TECHNE Corp net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-06-30 was $50.83M, a 39.78% increase year-over-year.
- BIO-TECHNE Corp net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-03-31 was $24.94M, a 32.85% decline year-over-year.
- BIO-TECHNE Corp net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-12-31 was $41.18M, a 6.85% increase year-over-year.
- BIO-TECHNE Corp net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-09-30 was $26.50M, a 16.75% decline year-over-year.
- BIO-TECHNE Corp net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was $143.45M, a 0.29% decline from fiscal 2016.
- BIO-TECHNE Corp net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was $143.87M, a 3.24% increase from fiscal 2015.
- BIO-TECHNE Corp net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was $139.36M, a 1.90% increase from fiscal 2014.
- BIO-TECHNE Corp net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was $136.76M, a 10.68% increase from fiscal 2013.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | $50.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $75.77M derived: sum of 2 quarters · filed 2017-09-07 | $116.95M derived: sum of 3 quarters · filed 2017-09-07 | $143.45M 10-K · filed 2017-09-07 |
| 2017-03-31 | $24.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | $66.12M derived: sum of 2 quarters · filed 2017-05-10 | $92.62M 10-Q · filed 2017-05-10 | $128.98M derived: sum of 4 quarters · filed 2017-09-07 |
| 2016-12-31 | $41.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $67.68M 10-Q · filed 2017-02-09 | $104.04M derived: sum of 3 quarters · filed 2017-09-07 | $141.18M derived: sum of 4 quarters · filed 2017-09-07 |
| 2016-09-30 | $26.50M 10-Q · filed 2016-11-09 | $62.86M derived: sum of 2 quarters · filed 2017-09-07 | $100.00M derived: sum of 3 quarters · filed 2017-09-07 | $138.54M derived: sum of 4 quarters · filed 2017-09-07 |
| 2016-06-30 | $36.36M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $73.50M derived: sum of 2 quarters · filed 2017-09-07 | $112.04M derived: sum of 3 quarters · filed 2017-09-07 | $143.87M 10-K · filed 2017-09-07 |
| 2016-03-31 | $37.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | $75.68M derived: sum of 2 quarters · filed 2017-05-10 | $107.51M 10-Q · filed 2017-05-10 | $144.65M derived: sum of 4 quarters · filed 2017-09-07 |
| 2015-12-31 | $38.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $70.37M 10-Q · filed 2017-02-09 | $107.51M derived: sum of 3 quarters · filed 2017-09-07 | $138.29M derived: sum of 4 quarters · filed 2017-09-07 |
| 2015-09-30 | $31.83M 10-Q · filed 2016-11-09 | $68.97M derived: sum of 2 quarters · filed 2017-09-07 | $99.75M derived: sum of 3 quarters · filed 2017-09-07 | $135.47M derived: sum of 4 quarters · filed 2017-09-07 |
| 2015-06-30 | $37.14M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $67.92M derived: sum of 2 quarters · filed 2017-09-07 | $103.64M derived: sum of 3 quarters · filed 2017-09-07 | $139.36M 10-K · filed 2017-09-07 |
| 2015-03-31 | $30.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10 | $66.50M derived: sum of 2 quarters · filed 2016-05-10 | $102.22M 10-Q · filed 2016-05-10 | $140.14M derived: sum of 4 quarters · filed 2016-08-29 |
| 2014-12-31 | $35.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09 | $71.44M 10-Q · filed 2016-02-09 | $109.36M derived: sum of 3 quarters · filed 2016-08-29 | $144.30M derived: sum of 4 quarters · filed 2016-08-29 |
| 2014-09-30 | $35.72M 10-Q · filed 2015-11-09 | $73.64M derived: sum of 2 quarters · filed 2016-08-29 | $108.57M derived: sum of 3 quarters · filed 2016-08-29 | $139.90M derived: sum of 4 quarters · filed 2016-08-29 |
| 2014-06-30 | $37.92M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-29 | $72.86M derived: sum of 2 quarters · filed 2016-08-29 | $104.18M derived: sum of 3 quarters · filed 2016-08-29 | $136.76M 10-K · filed 2016-08-29 |
| 2014-03-31 | $34.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | $66.26M derived: sum of 2 quarters · filed 2015-05-11 | $98.84M 10-Q · filed 2015-05-11 | |
| 2013-12-31 | $31.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-09 | $63.91M 10-Q · filed 2015-02-09 | ||
| 2013-09-30 | $32.59M 10-Q · filed 2014-11-10 | |||
| 2013-06-30 | $123.56M 10-K · filed 2015-08-31 | |||
| 2012-06-30 | $126.75M 10-K · filed 2014-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |